title: Cost-Effectiveness of Omalizumab in Chronic Idiopathic Urticaria Refractory to H1-Antihistamines in Turkey.
authors.affiliation: Hacettepe University, Ankara, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Tatar
authors.affiliation: Novartis Pharma, Istanbul, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Sezen
authors.affiliation: Polar Polar Health Economics & Policy, Ankara, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Senturk
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: M M
authors.initials: MM
authors.lastname: Balp
authors.affiliation: Novartis Pharma, Istanbul, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Saylan
authors.affiliation: Novartis Pharma, Istanbul, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Keskinaslan